- Capricor Therapeutics reported a first-quarter 2026 net loss of US$33.94 million, with basic loss per share from continuing operations of US$0.59, and also prepared to present at investor and patient conferences later in May.
- Analyst commentary highlighting optimism for potential FDA approval of Deramiocel alongside fresh uncertainty over its commercialization timing and milestones has become a key focus for investors reassessing Capricor’s outlook.
- We’ll now examine how the emerging regulatory and commercialization uncertainty around Deramiocel could reshape Capricor’s previously optimistic investment narrative.
AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Capricor Therapeutics Investment Narrative Recap
To own Capricor today, you need to believe Deramiocel can clear current FDA and commercialization hurdles and ultimately become a meaningful Duchenne therapy. The key near term catalyst remains the August 22, 2026 PDUFA decision, while the biggest risk is further delay or disruption to U.S. commercialization, particularly given rising losses and no product revenue. The latest earnings and analyst revisions reinforce those existing risks rather than creating a new one.
The most relevant update here is the analyst move to push assumed U.S. Deramiocel launch to 2027 after legal action involving NS Pharma and to remove an expected US$80.0 million milestone. That change goes straight to timing of any first commercial cash flows, heightening the importance of the FDA decision and Capricor’s ability to manage ongoing cash burn while Deramiocel’s path to market remains in flux.
Yet against this potentially promising FDA timeline, investors should be aware that commercialization delays and mounting losses could still...
Read the full narrative on Capricor Therapeutics (it's free!)
Capricor Therapeutics' narrative projects $245.5 million revenue and $109.6 million earnings by 2029.
Uncover how Capricor Therapeutics' forecasts yield a $54.67 fair value, a 85% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts take a much harsher view, assuming revenue only reaches about US$68.3 million by 2028 and that Capricor stays unprofitable, highlighting how far opinions can diverge on regulatory timing and dilution risk and why you may want to compare several scenarios before this new uncertainty is fully reflected in forecasts.
Explore 7 other fair value estimates on Capricor Therapeutics - why the stock might be worth just $31.66!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- Find 53 companies with promising cash flow potential yet trading below their fair value.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com